AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY澳大利亚与新西兰精神病学杂志
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY(英文缩写 AUST NZ J PSYCHIAT),ISSN 0004-8674,eISSN 1440-1614,中文译名:澳大利亚与新西兰精神病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.598 | Q2 |
| 2022 | 4.600 | Q2 |
| 2023 | 4.000 | Q1 |
| 2024 | 3.700 | Q1 |
| 2025 | 4.100 | Q1 |
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY 最新收录文献
-
1. Variables associated with variations in compulsory community treatment by health districts: A meta-regression analysis across four Australian jurisdictions.
PMID:日期:2026-09-30The use of compulsory community treatment in Australia varies widely within, and across, jurisdictions for reasons that are not fully understood. This study, therefore, used meta-regression to explore possible explanations for this variation in the following four Australian states: Queensland, South Australia, New South Wales and Victoria. Aggregated administrative data from the Australian Institute of Health and Welfare for 2018 were analysed, encompassing 402,060 individuals in contact with community mental health services. Meta-regression using logit-transformed proportions was employed to assess associations between compulsory community treatment rates and district-level sociodemographic variables, including age, sex, marital status, region of birth and metropolitan residence. Workforce data were also examined in New South Wales. Compulsory community treatment use varied significantly by jurisdiction and by health district within jurisdictions. Higher rates were associated with districts having more individuals aged 25-44 years, males (in South Australia), metropolitan residents, and those born outside Oceania. These associations persisted after adjustment. There was no statistically significant association between workforce levels and compulsory community treatment use in New South Wales. Our findings suggest that sociodemographic factors such as age, sex and place of residence or birth may explain some of the variation in compulsory community treatment use between health districts. The influence of sociodemographic variables and geographical location in influencing compulsory community treatment use at the health district level needs further investigation. Australian and New Zealand Clinical Trials Registry (https://www.anzctr.org.au/; ACTRN12624000153516).
-
4. Employment trajectories following the diagnosis and after long-acting injectable antipsychotic treatment in patients with schizophrenia: A nationwide study.
4. 精神分裂症患者确诊后及长效注射抗精神病药治疗后的就业轨迹：一项全国性研究PMID:日期:2026-09-12This study examined employment trajectories following the diagnosis and antipsychotic treatment of schizophrenia, with particular focus on transitions to long-acting injectable antipsychotic treatment. We conducted a nationwide matched cohort study using Taiwan's National Health Insurance Research Database (2001-2021). Individuals aged 18-64 years with newly diagnosed schizophrenia spectrum disorders were matched 1:1 with individuals without schizophrenia by birth year, sex, and index date. Employment trajectories were analyzed using controlled interrupted time-series models. To evaluate treatment-related transitions, individuals initiating long-acting injectable antipsychotics were compared with matched oral antipsychotic users. Subgroup analyses were conducted by illness duration and baseline medication adherence. The schizophrenia cohort (n = 93,041) showed substantially lower employment odds than matched comparisons (OR = 0.31), with a marked decline around diagnosis (OR = 0.90) and only modest recovery thereafter (post-diagnosis trend OR = 1.09 per year). In the treatment analysis (18,488 matched pairs), long-acting injectable users had lower baseline employment odds than oral antipsychotic users (OR = 0.85) and an immediate decline around long-acting injectable initiation (OR = 0.92), followed by a modestly more favorable post-initiation employment trend (OR = 1.03). More favorable post-initiation trends were observed among individuals with longer illness duration and lower baseline adherence. No meaningful differences in employment trajectories were observed across different long-acting injectable formulations, including flupentixol, risperidone, haloperidol, paliperidone, and fluphenazine. Employment outcomes in schizophrenia appear shaped by diagnostic and treatment-related transitions rather than static disease status. Stabilization after long-acting injectable initiation may be linked to incremental improvements in employment trajectories for some subgroups, but optimizing long-term vocational outcomes likely requires integrated psychosocial and vocational support.
-
5. Psychiatrists' and psychiatry trainees' perspectives of treatment priorities and the role of cognitive symptoms in supporting people with psychotic disorders.
PMID:日期:2026-09-10The treatment focus in psychotic disorders, like schizophrenia, is often the remission of positive symptoms despite neurocognitive impairments better predicting long-term outcomes. Cognitive remediation has substantial evidence for supporting reliable improvements in cognition in people affected by schizophrenia, but it remains underutilised. Understanding the barriers for cognitive remediation and cognitive testing implementation is critical to improving treatment outcomes in psychotic disorders. To address this, an online survey of psychiatrists and psychiatry trainees in Australia was undertaken to explore treatment priorities, referral practices, and confidence in treating people diagnosed with psychotic disorders. Statistical analyses were conducted using chi-square analyses, logistic regression and analysis of variance. Clinicians ( = 96) expressed confidence in their ability to treat those with psychotic disorders but were not as confident with regard to their ability to identify/treat cognitive symptoms in people with psychotic disorders. Despite acknowledging that cognitive symptoms were most predictive of functional outcomes (>75%), clinicians believed that patient concerns were primarily positive symptoms (>60%). Accordingly, treating positive symptoms was the highest priority in managing early psychosis (~90%), with cognitive symptoms rated as the lowest. Referral rates for cognitive testing or cognitive remediation were low (both < 30%). Despite the acknowledged relationship between cognitive symptoms and functional outcomes, and the evidence base for cognitive remediation efficacy, access to cognitive testing and cognitive remediation referral rates appear far from optimal. These findings should motivate mental health services to better incorporate cognitive screening to support the identification and prioritisation of cognitive symptoms.
-
6. Commentary on the ANZJP Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia - Where are the recommendations for methamphetamine-related psychoses?
PMID:日期:2026-09-09The ANZJP Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia provide strong recommendations when high-level evidence is available. For many clinical scenarios, however, there is insufficient evidence meaning that only weak recommendations can be made using the GRADE process. Concurrent methamphetamine use in people experiencing psychosis is one such scenario. The ANZJP GRADE guidelines offer only one weak recommendation, that people with comorbid schizophrenia and substance misuse be offered psychosocial interventions. Many clinicians would value additional recommendations for this common challenge in Australian mental health services. We consider the extent of the problem of methamphetamine-related psychosis in Australia and the heterogeneity of presentations that may be managed in clinical services. We summarise the existing evidence on treatment and highlight why research in this area remains scarce. Finally, we propose the development of a consensus framework to guide treatment of methamphetamine-related psychosis and, in so doing, to enable development of high(er)-level evidence with utility in real-world clinical settings.
-
8. Brief online parent-led early intervention for childhood autism: A randomised-controlled trial.
PMID:日期:2026-08-27Child behavioural and emotion regulation, and social communication; and parental confidence and mental health, all contribute to developmental outcomes for autistic children; however, there are limited programmes which integrate support across these domains. We report on a parallel, assessor-masked randomised controlled trial used to evaluate a brief, parent-led intervention, . Parents of 100 children aged 2-5 years with autism Level 2/3 and behavioural difficulties were randomly assigned (1:1) to ( = 49) or Waitlist ( = 51). involved 12-15 weekly 60- to 90-min online sessions of parenting intervention that covered three synergistic targets: child behavioural/emotional regulation, child social communication, and parental teamwork and mental health. Efficacy was assessed for primary (child conduct problems, Eyberg Child Behavior Inventory behavioural intensity and problem, and Social Responsiveness Scale, Second Edition autism features) and secondary (child social-emotional functioning and global functioning, parent sense of competence, parenting practices, mental health, and inter-parental conflict) outcomes. At postintervention, there were moderate to large improvements in the Intervention ( = 45) compared with the Waitlist group ( = 46) on three of four primary outcome measures: conduct problems (diff = -0.91, 95% confidence interval = -1.55 to -0.26), Eyberg Child Behavior Inventory intensity (diff = -27.84, 95% confidence interval = -43.76 to -11.92), and Social Responsiveness Scale, Second Edition total (diff = -11.76, 95% confidence interval = -22.84 to -0.68). Effects were maintained at 3-month follow-up. Improvements were found for all but one secondary outcome and did not significantly differ for mothers versus fathers. A brief synergistic intervention delivered by telehealth that integrates child and parenting domains has benefits across core and associated autism features, and positive functioning in parents, including fathers. ANZCTR #12618001866291 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381133&isReview=true.
-
10. Hospitalisation and mortality outcomes after second COVID-19 vaccination among Australians living with severe mental illness: Findings from a matched case-control study using national data linkage.
PMID:日期:2026-08-20To compare the proportion of Australians living with severe mental illness (target group) and the general population (comparator group) who received the first, second, and third doses of the COVID-19 vaccination between 22 February 2021 and 30 June 2022; examine the odds of any, non-psychiatric, and COVID-19-related hospitalisations within 12 months of the second vaccination; and examine the odds of all-cause and COVID-19-specific mortality within 12 months. We used a retrospective 1:4 age- and sex-matched case-control design. Subgroup analysis of individuals aged ⩾65 years old was also undertaken. This study used de-identified, linked administrative data from the Australian Immunisation Register, Pharmaceutical Benefits Scheme, Medicare Benefits Schedule, National Death Index, Demography data, and hospital records. The cohort included 375,335 individuals living with severe mental illness and 1,373,231 comparators. Between 22 February 2021 and 30 June 2022, the proportion of target group members receiving the first, second, and third doses was significantly lower than the comparators, albeit still high, and with a shorter average time between vaccinations. Adjusted odds of hospitalisation in the target group within 12 months of the second vaccination were 14.0 (95% CI = 13.8-14.2) for any, 9.7 (95% CI = 9.6-9.8) for non-psychiatric, and 19.0 (95% CI = 17.7-20.3) for COVID-19-related hospitalisations. Adjusted odds of all-cause mortality were 3.1 (95% CI = 3.0-3.1) and 9.4 (95% CI = 7.7-11.5) for COVID-19-related mortality. People with severe mental illness had significantly poorer hospitalisation and mortality outcomes after their second vaccination, highlighting persistent gaps in access and equity of care for this vulnerable population. ACTRN12624000117516.